geoscience.net logo
+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Switching between beta blockers in heart failure patients: rationale and practical considerations


, : Switching between beta blockers in heart failure patients: rationale and practical considerations. Congestive Heart Failure 9(5): 271-278

The clinical benefit of beta blockade has been proven in a variety of pathologic settings, including hypertension, angina pectoris, acute- and post-myocardial infarction, and congestive heart failure. However, beta blockers do not all share the same clinical outcomes with respect to efficacy or safety in many of these conditions. This is especially true in HF, where differences in reverse remodeling and effects on the periphery may be important differentiating factors leading to improved efficacy. In fact, beta blockers are a heterogeneous group of agents with respect to pharmacology, receptor biology, hemodynamic effects, and tolerability. As cardiovascular disease progresses, the issue of switching from one b blocker to another is an important consideration as to how to optimize the effectiveness of adrenergic blockade. Because of the differences among beta blockers, switching should be conducted in a manner that takes into account pharmacologic differences. For example, the similarities and differences of receptor subtype blockade of the two agents and the potential effects of ancillary properties. Two protocols for switching between carvedilol, a third-generation nonselective agent with vasodilation through alpha1 blockade, and a beta1-selective agent (e.g., metoprolol, atenolol) are described to simplify the process and maximize the safety and tolerability of this procedure. The optimal selection and use of adrenergic-blocking agents in the cardiovascular continuum will assist in providing improved management while minimizing safety and tolerability concerns.

US$29.90

PMID: 14564146


Other references

Vlietinck A.; Roets E.; Claes P.; Janssen G.; Vanderhaeghe H., 1973: Preparation of 6 epi phenoxymethyl penicillin and 6 epi benzyl penicillin. Journal of the Chemical Society Perkin Transactions I (9): 937-942

Dupré, A.; Christol, B.; Martinez, D., 1984: Multiple clustered histiocytofibroma. Annales de Dermatologie et de Venereologie 111(2): 163-164

Xu, G.; Lv, B.; Roberge, J.Y.; Xu, B.; Du, J.; Dong, J.; Chen, Y.; Peng, K.; Zhang, L.; Tang, X.; Feng, Y.; Xu, M.; Fu, W.; Zhang, W.; Zhu, L.; Deng, Z.; Sheng, Z.; Welihinda, A.; Sun, X., 2014: Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes. SGLT2 inhibitors deuterated at sites susceptible to oxidative metabolism were found to have a slightly longer tmax and half-life (t1/2), dose-dependent increase in urinary glucose excretion (UGE) in rats, and slightly superior effects on UGE in do...

Yaktapour, N.; Meiss, F.; Mastroianni, J.; Zenz, T.; Andrlova, H.; Mathew, N.R.; Claus, R.; Hutter, B.; Fröhling, S.; Brors, B.; Pfeifer, D.; Pantic, M.; Bartsch, I.; Spehl, T.S.; Meyer, P.T.; Duyster, J.; Zirlik, K.; Brummer, T.; Zeiser, R., 2015: BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF WT cells and those with mutations that activate or result in high levels of th...

Wunderlich, G., 1995: Property in, taxes on, agricultural land. The paper examines theories of property rights and public and private interests in property with regard to agricultural land. The real property tax is discussed as one among many features of the property system. Arguments are put forward for viewi...

Gorodetzky, C.W.; Cone, E.J.; Goldberg, S.R.; Herling, S.; Risner, M.E.; Shannon, H.E.; Vaupel, D.B., 1983: Progress report from the NIDA Addiction Research Center (preclinical laboratory), Lexington, Kentucky. Nida Research Monograph 43: 85-91

Cossmann, M., 1922: Synopsis illustre des mollusques de l'Eocene et de l'Oligocene en Aquitaine. Memoires de la Societe Geologique de France, 23: 5-112

Schwartz, A.N.; Freidenberg, D.; Harley, J.D., 1988: Nonselective angiography after intracorporal papaverine injection: an alternative technique for evaluating penile arterial integrity. Forty patients with impotence were evaluated by means of nonselective angiography after intracorporal papaverine injection. The penile arterial network was visualized in 39 patients (97%). The technique was technically simple, and there were no co...

Schuh, A., 2014: Recurrent neck pain. CT or MRI scan is not necessary in all cases!. Mmw Fortschritte der Medizin 156(10): 36-36

Dreze S.; Bailly C.; Asselineau D.; Nusgens B.; Darmon M.; Lapiere C., 1989: Synergism between human skin fibroblasts and keratinocytes to produce collagenase negative regulation by retinoids. Reichert, U And B Shroot (Ed ) Pharmacology And The Skin, Vol 3 Pharmacology Of Retinoids in The Skin; 8th Cird (Centre International De Recherches Dermatologiques) Symposium on Advances in Skin Pharmacology, Cannes, France, September 1-3, 1988 X+282p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 92-93